April 2007
PharmaEngine, Inc. 智擎生技製藥股份有限公司
(4162.TWO)
Investor Meeting Credit Suisse
C. Grace Yeh, Ph.D. President & CEO
Sept. 9, 2016
www.pharmaengine.com
2
PEP503 / NBTXR3
Korea MFDS accepted the submission of NDA (May 10, 2016)
Began marketing & sales in Taiwan
2016 Taipei Biotech Award (Go-Global Gold Medal Award )
CHMP positive opinion on MAA (July 22, 2016)
Company Operation
Expanded organization
Incorporated PharmaEngine Europe Sarl (Paris, France)
2016 Company of the Year Gold Award (Taiwan Bio Industry Organization)
ONIVYDE® (PEP02, MM-398, nal-IRI)
Ongoing enrollment of global pivotal study in soft tissue sarcoma
US FDA approved IND application in prostate cancer
Successful preliminary results from phase I/II trial in head & neck cancer
Highlights
Name:PharmaEngine, Inc. (智擎生技製藥股份有限公司)
Established:August 2002 (Operated since Feb. 2003)
Main field:Oncology
Lead Product: ONIVYDE®, Taiwan & US approval ( Oct. 22, 2015 )
Major investors : TTY Biopharm, National Development Fund
Chairman:Jeffrey Suen (孫致中)
President & CEO:C. Grace Yeh, Ph.D. (葉常菁)
Taiwan stock code:4162.TWO
Address:11F, 10 Minsheng E. Road, Sec. 3, Taipei 104, Taiwan
Subsidiary: PharmaEngine Europe Sarl (Paris, France)
Website : http://www.pharmaengine.com
Company Profile
3
4
Major Shareholders
Shareholder Number of Shares Percentage (%)
TTY Biopharm Co., Ltd. 19,701,275 19.30%
National Development Fund,
Executive Yuan 15,686,156 15.36%
Dr. Grace Yeh 4,341,194 4.25%
Center Laboratory Inc. 3,855,848 3.78%
Labor Retirement Fund 2,001,000 1.96%
CTBC Bank Co., Ltd in custody for
Forever One Investment Co., Ltd. 1,482,000 1.45%
Indus Asia Pacific Master Fund, Ltd. 900,000 0.88%
Mercuries Life Insurance Co., Ltd. 779,000 0.76%
Chiang Ching-Kuo Foundation for
International Scholarly Exchange 700,000 0.69%
HSBC Global Investment Funds - Asia
ex Japan Equity Smaller Companies 661,000 0.65%
Total 50,107,473 49.08%
*Updated in April 2016
2003 ~ 2007
2008 ~ 2009
2010 ~ 2013
History and Milestones
- Began operation
- In-licensed PEP02
- Started PEP02 phase I
- Red Herring Asia 100 award
- Started two PEP02 phase 2
- ASCO presentation
- Taipei Biotech Award
- Completed phase 2 gastric cancer in Europe and Asia
- Completed phase 2 pancreatic cancer in US and Taiwan - Out-licensed PEP02 - Started PEP02 (MM-398) global phase 3 pancreatic cancer (NAPOLI-1) - Initial public offering on Taiwan Gretai market (4162:TWO) - In-licensed PEP503 and PEP06 - Achieved enrollment goal of NAPOLI-1
- Phase 3 (NAPOLI-1) top-line data announced
- MM-398 NDA and MAA to US FDA, EMA, TFDA
- MAA accepted by EMA - Priority Review designated by US FDA - Set Up PharmaEngine Europe Sarl (Subsidiary) - ONIVYDE approvals in Taiwan and US - NDA application accepted by Korea MFDS - CHMP positive opinion of MAA
2014 ~ 2016
5
2010 ~ 2013
Drug Discovery Drug Development Marketing & Sales
Phase I Phase II Phase III Pre-Clinical Approval Market
CMO Partners
CRO Partners
Target Validated Target Lead
In-license Partners
PharmaEngine
Out-license Partners Hospitals &
organizations
No Research Development Only (NRDO)
Business Model NRDO & Networked Pharma
Contract Manufacturing
Organizations
Contract Research
Organizations
6
Networked Pharma
7
Created in 2016
8
Senior Management Team
C. Grace Yeh, Ph.D. - Founder, President & CEO
- Ph.D., Immunology, Medical U. of South Carolina, Charleston, SC, USA
- Blond McIndoe Center of Transplantation Biology, England; INSERM, France; T Cell Sciences,
CytoMed, Leukosite, Millennium (Cambridge, MA, USA)
Hubert Chan, MD, Ph.D.
- Vice President, Clinical & Regulatory Affairs
- MD, Chung Shan Medical School, Taichung, Taiwan; Ph.D., Pathobiology, U. of Minnesota, USA
- Certified Medical Oncologist, Cancer Centers; National Institute of Cancer Research, Tainan, Taiwan
Chishing Chang, CPA
- Vice President, Finance & Administration
- Master degree of Accounting, National Taiwan University, Taipei, Taiwan
- Certified Public Accountant (CPA); TTY Biopharm, MasterLink Securities, Sampo Securities
Alain Herrera, MD
- Head, Corporate Development; Managing Director, PharmaEngine Europe
- MD, Pitié-Salpétrière Hospital, Faculty of Medicine, Paris, France
- Alain Oncology Consulting, Global Oncology Business Strategy & Development, Sanofi, Paris, France; Chiron, Pierre Fabre, Roger Bellon, CNRS
Armand de Gramont, Ph.D. - Vice President, Translational Science
- Ph.D. in Cellular Biochemistry at Pierre et Marie Curie University, Paris, France
- Laboratory of Molecular and Cellular Biology, National Institutes of Health (NIH), USA; Head of the
New Drugs Evaluation Laboratory, Lausanne University Hospital, Lausanne, Switzerland
9
Scientific and Clinical Advisors
Scientific Advisory Board
Prof. Aimery de Gramont
- Head of Internal Medicine in Oncology,
French-British Institute Hospital, Paris, France
- Expert in gastrointestinal cancer (FOLFIRI, FOLFOX)
- Sponsor of the colorectal (PEPCOL) cancer study
Prof. David Cunningham
- Head of GI and Lymphoma units, Royal Marsden Hospital,
Sutton, UK
- Chief PI in gastric cancer phase II (PEP0206) study
Prof. Margaret Tempero
- Deputy Director, UCSF Helen Diller Family Comprehensive
Cancer Center, USA
- Participated in pancreatic phase II (PEP0208) study
Prof. Paul A. Bunn
- Prof., Univ. of Colorado Cancer Center, USA
- Expert in lung cancer
- Participated in the lung animal studies of PEP02
Prof. Li-Tzong Chen
- Director, National Institute of Cancer Research, Taiwan
- Expert in gastrointestinal cancer
- Participated in phase I, II, and III studies of PEP02
PharmaEngine Europe Sarl
Managing Director: Alain Herrera, MD
Address: 18 Rue du Dragon, 75006 Paris, France
Increase the source of in-licensing opportunities
Enhance the existing collaboration with Nanobiotix and scientific / clinical advisors
Establish closer relationship with European companies, CROs, and regulatory agencies
Apply government or EU grants to fund European-based development projects
10
Core Competence
PharmaEngine
Project evaluation &
licensing Cancer market
SWOT analysis
Development strategy & execution
Scale up & manufacturing
design Cooperation with oncology
experts
Clinical trial design & execution
Compliance with global regulations
Financial risk management
11
12
Product Mechanism Partner Start Territory Stage
PEP02 (MM-398)
ONIVYDE
Topo 1 Inhibitor
(Anti-cancer)
Merrimack
Pharmaceuticals (Nasdaq: MACK)
April 2003,
Sept. 2005,
May, 2011
Asia & Europe
(licensing-out)
US FDA
TFDA
Approval
PEP503 (NBTXR3)
Radiotherapy
Enhancer
(Anti-cancer)
Nanobiotix S.A (FP: NANO)
Aug. 2012 Asia-Pacific
(licensing-in)
Pivotal
PEP06 (NCE)
Novel mechanisms
(Anti-cancer)
Guangzhou BeBetter
Medicine
Technology
Jan. 2013 Worldwide (excluding China)
(licensing-in)
Drug
discovery
Pipeline and Partnership
(Irinotecan liposome injection)
13
ONIVYDE
安能得
Taiwan FDA & US FDA approvals (Oct. 22, 2015)
Included as category 1 recommendation in the NCCN clinical practice
guidelines (March 2016)
CHMP positive opinion on Marketing Authorization Application from
EMA (July 22, 2016)
14
Significance
The FIRST US FDA approved cancer drug in Taiwan, and the TFDA
approved it before the US FDA.
Onivyde is the FIRST cancer drug developed from preclinical to
regulatory approval in Taiwan.
Onivyde is the FIRST treatment in post-gemcitabine setting showing
a survival benefit in metastatic pancreatic cancer patients.
ONIVYDE (Irinotecan Liposome Injection, PEP02, MM-398, nal-IRI)
CPT-11
SN-38
Irinotecan (CPT-11) is a broad spectrum anti-cancer drug by blocking DNA
replication. It is approved for colorectal cancer with peak sales > US$1 billion.
ONIVYDE is a liposome formulation of irinotecan with sustained release profile
and preferential tumor accumulation (Enhanced Permeability and Retention
effect) and site-specific activation.
15
(CPT-11)
New Formulations of Irinotecan
New Formulations of Irinotecan, SN-38, or Camptothecin
Very few liposome drugs are approved
Project Company Formulation Stage
NKTR-102 Nektar, USA Pegylated irinotecan Phase 3
HA-irinotecan Alchemia, Australia Hyaluronic acid irinotecan Phase 3
CRLX101 Cerulean, USA Nanoparticle-camptothecin Phase 2
CPX-1 Celator, USA Liposome irinotecan-floxuridine Phase 2
NK-012 Nippon Kayaku, Japan Polymeric micelle SN-38 Phase 2
EZN-2208 Enzon, USA Pegylated SN-38 Phase 2
LE-SN38 NeoPharm, USA Liposome SN-38 Phase 2
AR-67 Arno Therapeutics, USA Camptothecin analogue Phase 2
IHL-305 Yakult/Terumo, Japan Liposome irinotecan Phase 1
Technical barriers
• Encapsulation & release
• Stability
• Scalability
16
• Liposomal doxorubicin (Doxil, Caelyx, Myocet)
• Liposomal daunorubicin (DaunoXome)
• Liposomal vincristine (Marqibo)
• Liposomal amphotericin B (AmBisome)
• Liposomal morphine (DepoDur)
Encapsulation efficiency > 95%, and optimal in vitro and in vivo release profile.
Completed process development to a scale of 1,000 vials per batch for GMP-
compliant production with 3-year stability data at 2- 8C.
Transferred manufacturing process to Merrimack, and they scaled up the
process to 5,000 vials per batch for the global phase 3 study, and more for
commercial launch.
Product Characteristics & Manufacturing
17
CRC 2nd-line
PIST-CRC-01
Solid Tumor PEP0201
Solid Tumor PEP0202
PEP0203
Brain
2nd-line (recurrent gliomas)
CRC 2nd-line PEPCOL
Pancreatic
2nd-line
NAPOLI-1
Pancreatic 2nd-line
PEP0208
Gastric
2nd-line PEP0206
GERCOR
NHRI UCSF
Phase I
Phase II
Phase III
Clinical Development
Ewing’s
sarcoma (Pediatric bone
cancers)
SPOC
18
> 700 patients treated with Onivyde in the clinical trials
Clinical Development Path
PEP0206 Randomized, Ph II in GAC
vs. CPT-11 vs. docetaxel iv, q3 weeks
ORR, PK, PGx
PEP0208 Ph II in PDAC iv, q3 weeks OS3m, PGx
PEP0203 Ph I, dose escalating
iv, q3 weeks + weekly HDFL, D1, D8
MTD, PK, PGx
PEP0201 Ph I, dose escalating
iv, q3 weeks MTD, PK study
PIST-CRC-01 Ph I, dose escalating
in mCRC iv, q2 weeks
MTD, PK, PGx
PEPCOL Randomized, Ph II in mCRC
FUPEP vs. FOLFIRI-1 or-3 iv, q2 weeks
ORR, PGx
NAPOLI-1 Randomized, Ph III in PDAC
vs. 5-FU/LV vs. FUPEP iv, q2 or q3 weeks
OS, PK, PGx
19
20
NAPOLI-1*
An open label, randomized phase 3 study of MM-398
with or without 5-Fluorouracil/Leucovorin (5-FU/LV),
versus 5-FU/LV in Patients with Metastatic Pancreatic
Cancer
Principal Investigator: Daniel D. von Hoff, M.D., F.A.C.P
TGen, University of Arizona, Mayo Clinic and Scottsdale Healthcare
*NAPOLI: Nanoliposomal irinotecan
Wang-Gillam, A., et al., Lancet, 387: 545-557, 2016
Phase 3 (NAPOLI-1) Updated Data Shows ONIVYDE® Combination Regimen
Increased One Year Survival by 63% in Metastatic Pancreatic Cancer
One year overall survival estimates of 26%
A well-defined safety and tolerability profile
CA19-9 levels are associated with the treatment effect
21
NAPOLI-1 Data Demonstrates ONIVYDE® Regimen Maintains
Quality of Life While Improving Overall Survival in Patients with
Metastatic Pancreatic Cancer
Methodology :
A total of 154 patients (ONIVYDE in combination with 5-FU and leucovorin,
n=71; 5-FU and leucovorin, n=83) comprised the population for this analysis.
Results:
ONIVYDE combination regimen were able to maintain quality of life over 12
weeks and there were no significant differences versus the 5-FU and
leucovorin-treated patients in quality of life response despite the addition of a
second chemotherapeutic agent.
25
Projected Cancer Deaths (2010-2030)
24
Front line treatment
Treatment Approval Global Sales / $US
Gemcitabine (GEM)
(Gemzar® , Eli Lilly ) 1996 US FDA 2 billion (2007)
Erlotinib + GEM
(Tarceva® , Roche) 2005 US FDA 400 million (2013)
Abraxane + GEM
(Abraxane® , Celgene) 2013 US FDA 960 million (2015)
1994 1998 2002 2006 2013 2015
Gemcitabine Erlotinib + GEM Abraxane + GEM
Post-Gem treatment
ONIVYDE + 5-FU/LV
Approved first line treatment
ONIVYDE + 5-FU/LV is the FIRST treatment in post-gemcitabine setting
showing a survival benefit in this aggressive disease.
Pancreatic Cancer Landscape
25
Product Company /
Partner
Mechanism
of Action
Design Patient
type & No.
Data Development
status (press
release date)
TH-302
(evofosfamide)
Threshold
/ Merck KGaA
Hypoxia-
activated
drug
Phase 3, TH-
302 + gem vs.
placebo + gem
(MAESTRO)
1st line, n =
693
HR = 0.84, p =
0.0589
Terminated
(12/7/2015)
Ruxolitinib Incyte /
Novartis
JAK1/JAK2
inhibitor
Phase 3, Rux +
capecitabine vs.
capecitabine
(JANUS 1)
2nd line, n =
318, CRP-
high
No sufficient
level of efficacy
in planned
interim analysis
Terminated
(2/11/2016)
90Y-
clivatuzumab
Immunomedics Radioimmu
no-
conjugate
to MUC1
Phase 3, 90Y-Cl
+ low gem vs.
placebo + low
gem (PANCRIT-
1)
3rd line, n =
334
No sufficient
level of efficacy
in planned
interim analysis
Terminated
(3/14/2016)
Algenpantucel
-L
NewLink
Genetics
Cancer
vaccine
expressing
alpha-gal
Phase 3,
Algenpantucel-
L vs. standard
of care
(IMPRESS)
Resected, n
= 722
OS = 27.3 m vs.
30.4 m
Terminated
(5/9/2016)
Necuparanib
(M402)
Momenta
Pharmaceuticals
Heparan
sulfate-like
mimetic
Phase 2, M402
+ Abraxane
+gem vs.
Abraxane +gem
1st line, n =
180, 120
randomized
before
termination
No sufficient
level of efficacy
in planned
interim futility
analysis
Terminated
(8/4/2016)
Recent Failures in Advanced
Pancreatic Cancer (12/2015 - 8/2016)
26
Ref: Merrimack conference call in Jan. 2016
ONIVYDE Market Potential
Merrimack launched ONIVYDE in the US on October 26, 2015
US pricing
Onivyde is priced at ~ US$1,620 per vial.
3-4 vials every two weeks, monthly costs ~ US$11,200.
With an average four-month regimen, per patient treatment ~US$43,000.
US sales (net product revenues)
Q4 2015 (2 months): $4.3 million, Q1 2016 : $10.0 million, Q2 : $12.9 million
18,500 potential post-gemcitabine patients may receive treatment
of Onivyde plus 5-FU/LV.
Potential US peak sales of post-gemcitabine pancreatic cancer:
~ US$800 million
MACK conference calls on Aug. 4, 2016
US Sales
27
Commentaries of ONIVYDE
Published online, Nov. 22, 2015
…. few treatment options
currently exist for patients
who have progressed on
first-line gemcitabine-
based therapy …. Hence,
a confirmed survival
benefit in this population
of patients with an unmet
clinical need is especially
exciting.
Published, Sep, 2015
Second-line therapy of
pancreatic cancer has to be
considered in terms of risk
benefit for the patient…... MM-
398 when available in all
countries may be the best
option for second-line treatment
of these patients.
Published online, Apr. 14, 2015
Management of metastatic pancreatic
cancer: Current treatment options and
potential new therapeutic targets Francesco Sclafani, Ridhima Iyer, David Cunningham,
Naureen Starling∗The Royal Marsden NHS Foundation
Trust, London and Surrey, UK
…… it is likely that, based on
the results of this phase III
trial, MM-398 will be granted
formal approval by the
regulatory agencies and soon
become an established
alternative treatment option in
the second line setting of
metastatic PDA.
28
ONIVYDE® as Category 1 Treatment Option in
the 2016 NCCN Guidelines
A category 1 classification represents the highest
level of evidence and uniform NCCN consensus
that the intervention is appropriate.
30
Indication Development Stage
Preclinical Phase I Phase II Phase III NDA
Pancreatic cancer
(Post-Gem) Approved
Pancreatic cancer
(Front-line) Ongoing Data in 2017
Small cell lung cancer
(Second-line) Planning Start in 2016
Colorectal cancer
(Second-line, DOUBLIRI) Ongoing Started in 2015
Ewing's sarcoma
(Pediatric bone tumor) Ongoing Data in 2016
Brain cancer
(Recurrent glioma, CED) Ongoing Data in 2016
Breast cancer
(Metastatic) Ongoing Data in 2016
Colorectal cancer
(Front-line, with anti-EGFR) Ongoing Started in 2016
30
Life Cycle Management
Merrimack corporate overview in July 2016
Potential future development as a combination backbone with
targeted therapy and immuno-oncology therapy
2003
31
2011
2014
US$220 million +
Tiered royalty rate based on the net sales in Europe and Asia
US$970 million
(including US$46.5 million, sublicense revenue to PEI)
Financial Transactions
2015
2016
US$32 billion
US$3 million
Shire acquired Baxalta
(May 2016)
PharmaEngine is eligible to receive up to US$266.5 million plus tiered royalty,
so far received US$48 million
32
Payment Terms
1) Licensing
milestone
US$220 million
(Merrimack)
plus US$46.5
million
(Baxalta)
Upfront US$10 million (May 2011)
Development
& Regulatory
milestone
US$5 million (Feb.2012, phase III 1st patient in)
US$7 million (Sep.2014, amend Agreement with MACK)
US$5 million (April 2015, Completed NDA Submission to US FDA )
US$11 million (June 2015, MAA Acceptance by EMA )
US$10 million (May 2016, Korea MFDS accepted submission NDA )
(Future milestone payment: US$88.5 million)
Sales
Milestone
Based on reaching certain net sales in Europe and Asia
(Future milestone payment: US$130 million)
2) Royalty Tiered royalty rate based on the net sales in Europe and Asia
3) Others All future development costs reimbursed by Merrimack.
Product sales in Taiwan belong to PharmaEngine.
ONIVYDE Licensing Deal
33
PEP503
(Crystalline Hafnium Oxide, NBTXR3)
34
Nanobiotix is a spin-off from the State University of New York (SUNY)
at Buffalo and was incorporated in 2003.
More than 50 employees and is based in Paris, France.
IPO in Oct. 2012. (FP: NANO)
Exclusive license agreement for Asia Pacific region executed in
August 2012, Nanobiotix is eligible for US$57 million and up to double
digit royalty, so far paid US$3 million to Nanobiotix.
Licensing Partner-Nanobiotix
PEP503 (Crystalline Hafnium Oxide)
Crystalline
HfO2 coating
RT dose (Gy)
Pro
babili
ty
10 20 30 40 50 60 70 80
1
0.5
0
CureAdverse eventTherapeutic window
standard
radiotherapywith
NanoXray
RT dose (Gy)
Pro
ba
bility
10 20 30 40 50 60 70 80
1
0.5
0
CureAdverse eventTherapeutic window
Maximal Tolerated Dose Maximal Tolerated Dose
35
PEP503 (NBTXR3) is a nanoparticle formulation of hafnium oxide crystal for the
local treatment of tumors to enhance the efficacy of radiotherapy.
NBTXR3 has been classified in the EU as class III medical device.
Efficacy Evaluation of Phase 1 STS
36
The recommended volume for the pivotal study is 10%.
Intra-tumor Bioavailability
3D visualization demonstrated the persistence over time and optimal
bioavailability of NBTXR3 during all sessions of RTx.
37
Global Pivotal (Phase II/III) Study
Population: Patients with soft tissue sarcoma of the
extremity and trunk wall
End points
Complete pathological
response rate (pCR)
Tumor shrinkage rate and
operability
Progression free survival
(local and distant)
Amputation rate
Study Design
Stratification Population:
myxoid liposarcomas vs others
* Two-arms, randomized, active-controlled, multi-center, and open-label
trial
R 1:1
Study Arm (78 pts):
NBTXR3 + RT (50 Gy – 2 GyF)
Comparator Arm (78 pts):
RT alone (50 Gy – 2 GyF)
156 patients
Target Population
♦ Locally advanced soft tissue sarcoma of the extremity and trunk wall
♦ All grades
♦ Candidate to radiotherapy + surgery (ESMO guideline)
a) Primary tumor or,
b) Relapsed tumor, localized out of previously irradiated area
38 CONFIDENTIAL
Phase I/II H&N Cancer Study Design
Efficacy of PEP503 in H & N Cancer Study
Safety of PEP503 in H & N Cancer Study
42
2016 2017 2018 2019 2020
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3
Q4
Soft tissue sarcoma
Pivotal Trial
(Nanobiotix, PharmaEngine) Global
Head & neck cancer
Phase I/II (Nanobiotix)
France
Liver cancer Phase I/II
(Nanobiotix) EU
Rectal cancer Phase I/II
(PharmaEngine) Taiwan
Prostate cancer
Phase I
(Nanobiotix) US
PEP503 Development Timeline
Pivotal phase II/III trial in STS, it is the final step before registration (CE mark).
US FDA approved IND in prostate cancer (Jan. 2016).
PharmaEngine expands the clinical applications in rectal and head & neck cancers.
PEP06
(New Chemical Entity)
with
New Projects Under Evaluation
43
Hallmarks of Cancer
44
45
2015 2016 2017 2018
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
PEP06 Discovery Preclinical Phase 1
New Projects Preclinical, Phase 1, or Phase 2
PharmaEngine holds worldwide rights of PEP06 with the exception of China,
while BeBetter keeps the respective rights in China.
Filed a patent application for new drug candidates of PEP06
Evaluation of new projects ongoing
New Projects Development Timeline
46
Product Indication Development stage
Research Pre-
clinical Phase 1 Phase 2 Phase 3 NDA
PEP02 (MM-398) (Irinotecan liposomal
injection)
ONIVYDE®
Pancreatic cancer (post-gem)
Approved
Pancreatic cancer (Front-line) Ongoing
Small cell lung cancer (Second-line)
Planning Planning
Colorectal cancer (Second-line)
Ongoing
Ewing's sarcoma (Pediatric Solid Tumors)
Ongoing
Brain cancer (Recurrent Gliomas)
Ongoing
Breast cancer (Metastatic)
Ongoing
PEP503 (NBTXR3) (Crystalline hafnium
oxide)
Soft tissue sarcoma (Nanobiotix, PharmaEngine) Pivotal Trial
Head & neck cancer (Nanobiotix) Ongoing
Liver cancer (Nanobiotix) Ongoing
Rectal cancer (PharmaEngine) Ongoing
Prostate cancer (Nanobiotix) Planning
PEP06 (New Chemical Entity)
Solid tumor Ongoing 46
Portfolio Status
2011 2012 2013 2014 2015 2016 H1
47
2011 2012 2013 2014 2015 2016H1
Profit after tax (NTD,000)
285,707
48,987
123,592
394,022
165,000
117,800
EPS
4.01
-1.23
1.23
3.87
1.62
0.58
2015 dividend:Cash NTD2 & stock NTD2
Revenue Performance
US
Global Collaboration
48
EU China & Asia